Electrical devices and anti-scarring drug combinations
First Claim
Patent Images
1. A medical device comprising an electrical device and an anti-scarring drug combination;
- wherein said electrical device is selected from the group consisting of;
a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device;
wherein said anti-scarring drug combination is selected from;
amoxapine and prednisolone;
paroxetine and prednisolone;
dipyridamole and prednisolone;
dexamethasone and econazole;
diflorasone and alprostadil;
dipyridamole and amoxapine;
dipyridamole and ibudilast;
nortriptyline and loratadine;
nortriptyline and desloratadine;
albendazole and pentamidine;
itraconazole and lovastatin;
terbinafine and manganese sulfate;
a triazole and an aminopyridine, an antiprotozoal and a diaminopyridine, an antiprotozoal and a quaternary ammonium compound;
an aromatic diamidine and a compound selected from the group consisting of;
an antiestrogen, an anti-fungal imidazole, disulfuram, and ribavirin;
an aminopyridine and a compound selected from the group consisting of;
phenothiazine, dacarbazine, or phenelzine;
a quaternary ammonium compound and a compound selected from the group consisting of;
an anti-fungal imidazole, halopnogin, MnSO4, and ZnCl2;
an antiestrogen and at least one compound selected from the group consisting of;
phenothiazine, cupric chloride, dacarbazine, methoxsalen, and phenelzine;
an antifungal imidazone and at least one compound selected from a group consisting of;
disulfuram and ribavirin;
an estrogenic compound and dacarbazine;
amphotericin B and dithiocarbamoyl disulfide;
terbinafine and a manganese compound;
a tricyclic antidepressant and a corticosteroid;
a tetra-substituted pyrimidopyrimidine and a corticosteroid;
a prostaglandin and a retinoid;
an azole and a steroid;
a steroid and a compound selected from the group consisting of;
a prostaglandin, a beta-adrenergic receptor ligand, an anti-mitotic agent, and a microtubule inhibitor;
a corticosteroid and either a serotonin norepinephrine reuptake inhibitor or a naradrenaline reuptake inhibitor;
a non-steroidal immunophilin-dependent immunosuppressant and a non-steroidal immunophilin-dependent immunosuppressant enhancer;
an antihistamine and a compound selected from the group consisting of a corticosteroid, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, and a steroid receptor modulator;
a tricyclic compound and a corticosteroid;
an antipsychotic drug and an antiprotozoal drug;
an antihelmintic drug and an antiprotozoal drug;
ciclopirox and an antiproliferative agent;
a salicylanilide and an antiproliferative agent;
pentamidine and chlorpromazine;
an antihelmintic drug and an antiprotozoal drug;
dibucaine and a vinca alkaloid;
an amide local anaesthetic related to bupivacaine and a vinca alkaloid;
pentamidine and an antiproliferative agent;
a triazole and an antiarrhythmic agent;
an azole and an HMG-CoA reductase inhibitor;
a phenothiazine conjugate;
phenothiazine and an antiproliferative agent;
a kinesin inhibitor and an antiproliferative agent;
an agent that reduces the biological activity of a mitotic kinesin and an agent that reduces the biological activity of protein tyrosine phosphatase;
an anti-inflammatory agent and an agent selected from group consisting of an anti-depressant, an SSRI, a cardiovascular agent, an anti-fungal agent, and prostaglandin;
a cardiovascular drug and an antidepressant;
a cardiovascular drug and a phosphodiesterase IV inhibitor;
an antidepressant and an antihistamine;
an anti-fungal agent and an HMG-CoA reductase inhibitor; and
an antifungal agent and a metal ion; and
wherein said anti-scarring drug combination inhibits scarring between said electrical device and a host into which said electrical device is implanted.
0 Assignments
0 Petitions
Accused Products
Abstract
Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
-
Citations
4 Claims
-
1. A medical device comprising an electrical device and an anti-scarring drug combination;
-
wherein said electrical device is selected from the group consisting of;
a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device;
wherein said anti-scarring drug combination is selected from;
amoxapine and prednisolone;
paroxetine and prednisolone;
dipyridamole and prednisolone;
dexamethasone and econazole;
diflorasone and alprostadil;
dipyridamole and amoxapine;
dipyridamole and ibudilast;
nortriptyline and loratadine;
nortriptyline and desloratadine;
albendazole and pentamidine;
itraconazole and lovastatin;
terbinafine and manganese sulfate;
a triazole and an aminopyridine, an antiprotozoal and a diaminopyridine, an antiprotozoal and a quaternary ammonium compound;
an aromatic diamidine and a compound selected from the group consisting of;
an antiestrogen, an anti-fungal imidazole, disulfuram, and ribavirin;
an aminopyridine and a compound selected from the group consisting of;
phenothiazine, dacarbazine, or phenelzine;
a quaternary ammonium compound and a compound selected from the group consisting of;
an anti-fungal imidazole, halopnogin, MnSO4, and ZnCl2;
an antiestrogen and at least one compound selected from the group consisting of;
phenothiazine, cupric chloride, dacarbazine, methoxsalen, and phenelzine;
an antifungal imidazone and at least one compound selected from a group consisting of;
disulfuram and ribavirin;
an estrogenic compound and dacarbazine;
amphotericin B and dithiocarbamoyl disulfide;
terbinafine and a manganese compound;
a tricyclic antidepressant and a corticosteroid;
a tetra-substituted pyrimidopyrimidine and a corticosteroid;
a prostaglandin and a retinoid;
an azole and a steroid;
a steroid and a compound selected from the group consisting of;
a prostaglandin, a beta-adrenergic receptor ligand, an anti-mitotic agent, and a microtubule inhibitor;
a corticosteroid and either a serotonin norepinephrine reuptake inhibitor or a naradrenaline reuptake inhibitor;
a non-steroidal immunophilin-dependent immunosuppressant and a non-steroidal immunophilin-dependent immunosuppressant enhancer;
an antihistamine and a compound selected from the group consisting of a corticosteroid, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, and a steroid receptor modulator;
a tricyclic compound and a corticosteroid;
an antipsychotic drug and an antiprotozoal drug;
an antihelmintic drug and an antiprotozoal drug;
ciclopirox and an antiproliferative agent;
a salicylanilide and an antiproliferative agent;
pentamidine and chlorpromazine;
an antihelmintic drug and an antiprotozoal drug;
dibucaine and a vinca alkaloid;
an amide local anaesthetic related to bupivacaine and a vinca alkaloid;
pentamidine and an antiproliferative agent;
a triazole and an antiarrhythmic agent;
an azole and an HMG-CoA reductase inhibitor;
a phenothiazine conjugate;
phenothiazine and an antiproliferative agent;
a kinesin inhibitor and an antiproliferative agent;
an agent that reduces the biological activity of a mitotic kinesin and an agent that reduces the biological activity of protein tyrosine phosphatase;
an anti-inflammatory agent and an agent selected from group consisting of an anti-depressant, an SSRI, a cardiovascular agent, an anti-fungal agent, and prostaglandin;
a cardiovascular drug and an antidepressant;
a cardiovascular drug and a phosphodiesterase IV inhibitor;
an antidepressant and an antihistamine;
an anti-fungal agent and an HMG-CoA reductase inhibitor; and
an antifungal agent and a metal ion; and
wherein said anti-scarring drug combination inhibits scarring between said electrical device and a host into which said electrical device is implanted.
-
-
2. A method for inhibiting scarring comprising placing an electrical device and an anti-scarring drug combination into an animal host,
wherein said electrical device is selected from the group consisting of: - a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device;
wherein said anti-scarring drug combination is selected from;
amoxapine and prednisolone;
paroxetine and prednisolone;
dipyridamole and prednisolone;
dexamethasone and econazole;
diflorasone and alprostadil;
dipyridamole and amoxapine;
dipyridamole and ibudilast;
nortriptyline and loratadine;
nortriptyline and desloratadine;
albendazole and pentamidine;
itraconazole and lovastatin;
terbinafine and manganese sulfate;
a triazole and an aminopyridine, an antiprotozoal and a diaminopyridine, an antiprotozoal and a quaternary ammonium compound;
an aromatic diamidine and a compound selected from the group consisting of;
an antiestrogen, an anti-fungal imidazole, disulfuram, and ribavirin;
an aminopyridine and a compound selected from the group consisting of;
phenothiazine, dacarbazine, or phenelzine;
a quaternary ammonium compound and a compound selected from the group consisting of;
an anti-fungal imidazole, halopnogin, MnSO4, and ZnCl2;
an antiestrogen and at least one compound selected from the group consisting of;
phenothiazine, cupric chloride, dacarbazine, methoxsalen, and phenelzine;
an antifungal imidazone and at least one compound selected from a group consisting of;
disulfuram and ribavirin;
an estrogenic compound and dacarbazine;
amphotericin B and dithiocarbamoyl disulfide;
terbinafine and a manganese compound;
a tricyclic antidepressant and a corticosteroid;
a tetra-substituted pyrimidopyrimidine and a corticosteroid;
a prostaglandin and a retinoid;
an azole and a steroid;
a steroid and a compound selected from the group consisting of;
a prostaglandin, a beta-adrenergic receptor ligand, an anti-mitotic agent, and a microtubule inhibitor;
a corticosteroid and either a serotonin norepinephrine reuptake inhibitor or a naradrenaline reuptake inhibitor;
a non-steroidal immunophilin-dependent immunosuppressant and a non-steroidal immunophilin-dependent immunosuppressant enhancer;
an antihistamine and a compound selected from the group consisting of a corticosteroid, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, and a steroid receptor modulator;
a tricyclic compound and a corticosteroid;
an antipsychotic drug and an antiprotozoal drug;
an antihelmintic drug and an antiprotozoal drug;
ciclopirox and an antiproliferative agent;
a salicylanilide and an antiproliferative agent;
pentamidine and chlorpromazine;
an antihelmintic drug and an antiprotozoal drug;
dibucaine and a vinca alkaloid;
an amide local anaesthetic related to bupivacaine and a vinca alkaloid;
pentamidine and an antiproliferative agent;
a triazole and an antiarrhythmic agent;
an azole and an HMG-CoA reductase inhibitor;
a phenothiazine conjugate;
phenothiazine and an antiproliferative agent;
a kinesin inhibitor and an antiproliferative agent;
an agent that reduces the biological activity of a mitotic kinesin and an agent that reduces the biological activity of protein tyrosine phosphatase;
an anti-inflammatory agent and an agent selected from group consisting of an anti-depressant, an SSRI, a cardiovascular agent, an anti-fungal agent, and prostaglandin;
a cardiovascular drug and an antidepressant;
a cardiovascular drug and a phosphodiesterase IV inhibitor;
an antidepressant and an antihistamine;
an anti-fungal agent and an HMG-CoA reductase inhibitor; and
an antifungal agent and a metal ion; and
wherein said anti-scarring drug combination inhibits scarring.
- a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device;
-
3. A method for making a medical device comprising combining an electrical device and an anti-scarring drug combination,
wherein said electrical device is selected from the group consisting of: - a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device;
wherein said anti-scarring drug combination is selected from;
amoxapine and prednisolone;
paroxetine and prednisolone;
dipyridamole and prednisolone;
dexamethasone and econazole;
diflorasone and alprostadil;
dipyridamole and amoxapine;
dipyridamole and ibudilast;
nortriptyline and loratadine;
nortriptyline and desloratadine;
albendazole and pentamidine;
itraconazole and lovastatin;
terbinafine and manganese sulfate;
a triazole and an aminopyridine, an antiprotozoal and a diaminopyridine, an antiprotozoal and a quaternary ammonium compound;
an aromatic diamidine and a compound selected from the group consisting of;
an antiestrogen, an anti-fungal imidazole, disulfuram, and ribavirin;
an aminopyridine and a compound selected from the group consisting of;
phenothiazine, dacarbazine, or phenelzine;
a quaternary ammonium compound and a compound selected from the group consisting of;
an anti-fungal imidazole, halopnogin, MnSO4, and ZnCl2;
an antiestrogen and at least one compound selected from the group consisting of;
phenothiazine, cupric chloride, dacarbazine, methoxsalen, and phenelzine;
an antifungal imidazone and at least one compound selected from a group consisting of;
disulfuram and ribavirin;
an estrogenic compound and dacarbazine;
amphotericin B and dithiocarbamoyl disulfide;
terbinafine and a manganese compound;
a tricyclic antidepressant and a corticosteroid;
a tetra-substituted pyrimidopyrimidine and a corticosteroid;
a prostaglandin and a retinoid;
an azole and a steroid;
a steroid and a compound selected from the group consisting of;
a prostaglandin, a beta-adrenergic receptor ligand, an anti-mitotic agent, and a microtubule inhibitor;
a corticosteroid and either a serotonin norepinephrine reuptake inhibitor or a naradrenaline reuptake inhibitor;
a non-steroidal immunophilin-dependent immunosuppressant and a non-steroidal immunophilin-dependent immunosuppressant enhancer;
an antihistamine and a compound selected from the group consisting of a corticosteroid, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, and a steroid receptor modulator;
a tricyclic compound and a corticosteroid;
an antipsychotic drug and an antiprotozoal drug;
an antihelmintic drug and an antiprotozoal drug;
ciclopirox and an antiproliferative agent;
a salicylanilide and an antiproliferative agent;
pentamidine and chlorpromazine;
an antihelmintic drug and an antiprotozoal drug;
dibucaine and a vinca alkaloid;
an amide local anaesthetic related to bupivacaine and a vinca alkaloid;
pentamidine and an antiproliferative agent;
a triazole and an antiarrhythmic agent;
an azole and an HMG-CoA reductase inhibitor;
a phenothiazine conjugate;
phenothiazine and an antiproliferative agent;
a kinesin inhibitor and an antiproliferative agent;
an agent that reduces the biological activity of a mitotic kinesin and an agent that reduces the biological activity of protein tyrosine phosphatase;
an anti-inflammatory agent and an agent selected from group consisting of an anti-depressant, an SSRI, a cardiovascular agent, an anti-fungal agent, and prostaglandin;
a cardiovascular drug and an antidepressant;
a cardiovascular drug and a phosphodiesterase IV inhibitor;
an antidepressant and an antihistamine;
an anti-fungal agent and an HMG-CoA reductase inhibitor; and
an antifungal agent and a metal ion; and
wherein said anti-scarring drug combination inhibits scarring between said electrical device and a host into which said electrical device is implanted.
- a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device;
-
4. A method for implanting an electrical device comprising:
-
(a) infiltrating a tissue of a host where said electrical device is to be implanted with an anti-scarring drug combination; and
(b) implanting said electrical device into said host;
wherein said electrical device is selected from the group consisting of;
a neurostimulator, a sacral nerve stimulator, a gastric nerve stimulator, a cochlear implant, a bone growth stimulator, a cardiac pacemaker, an implantable cardioverter defibrillator system, a vagus nerve stimulator, an electrical lead, and a cardiac rhythm management device; and
wherein said anti-scarring drug combination is selected from;
amoxapine and prednisolone;
paroxetine and prednisolone;
dipyridamole and prednisolone;
dexamethasone and econazole;
diflorasone and alprostadil;
dipyridamole and amoxapine;
dipyridamole and ibudilast;
nortriptyline and loratadine;
nortriptyline and desloratadine;
albendazole and pentamidine;
itraconazole and lovastatin;
terbinafine and manganese sulfate;
a triazole and an aminopyridine, an antiprotozoal and a diaminopyridine, an antiprotozoal and a quaternary ammonium compound;
an aromatic diamidine and a compound selected from the group consisting of;
an antiestrogen, an anti-fungal imidazole, disulfuram, and ribavirin;
an aminopyridine and a compound selected from the group consisting of;
phenothiazine, dacarbazine, or phenelzine;
a quaternary ammonium compound and a compound selected from the group consisting of;
an anti-fungal imidazole, halopnogin, MnSO4, and ZnCl2;
an antiestrogen and at least one compound selected from the group consisting of;
phenothiazine, cupric chloride, dacarbazine, methoxsalen, and phenelzine;
an antifungal imidazone and at least one compound selected from a group consisting of;
disulfuram and ribavirin;
an estrogenic compound and dacarbazine;
amphotericin B and dithiocarbamoyl disulfide;
terbinafine and a manganese compound;
a tricyclic antidepressant and a corticosteroid;
a tetra-substituted pyrimidopyrimidine and a corticosteroid;
a prostaglandin and a retinoid;
an azole and a steroid;
a steroid and a compound selected from the group consisting of;
a prostaglandin, a beta-adrenergic receptor ligand, an anti-mitotic agent, and a microtubule inhibitor;
a corticosteroid and either a serotonin norepinephrine reuptake inhibitor or a naradrenaline reuptake inhibitor;
a non-steroidal immunophilin-dependent immunosuppressant and a non-steroidal immunophilin-dependent immunosuppressant enhancer;
an antihistamine and a compound selected from the group consisting of a corticosteroid, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, and a steroid receptor modulator;
a tricyclic compound and a corticosteroid;
an antipsychotic drug and an antiprotozoal drug;
an antihelmintic drug and an antiprotozoal drug;
ciclopirox and an antiproliferative agent;
a salicylanilide and an antiproliferative agent;
pentamidine and chlorpromazine;
an antihelmintic drug and an antiprotozoal drug;
dibucaine and a vinca alkaloid;
an amide local anaesthetic related to bupivacaine and a vinca alkaloid;
pentamidine and an antiproliferative agent;
a triazole and an antiarrhythmic agent;
an azole and an HMG-CoA reductase inhibitor;
a phenothiazine conjugate;
phenothiazine and an antiproliferative agent;
a kinesin inhibitor and an antiproliferative agent;
an agent that reduces the biological activity of a mitotic kinesin and an agent that reduces the biological activity of protein tyrosine phosphatase;
an anti-inflammatory agent and an agent selected from group consisting of an anti-depressant, an SSRI, a cardiovascular agent, an anti-fungal agent, and prostaglandin;
a cardiovascular drug and an antidepressant;
a cardiovascular drug and a phosphodiesterase IV inhibitor;
an antidepressant and an antihistamine;
an anti-fungal agent and an HMG-CoA reductase inhibitor; and
an antifungal agent and a metal ion.
-
Specification